- Home
- GRCE vs OMIC Comparison
GRCE vs OMIC Comparison
Compare GRCE & OMIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRCE
- OMIC
- Stock Information
- Founded
- GRCE 2002
- OMIC 2016
- Country
- GRCE United States
- OMIC United States
- Employees
- GRCE N/A
- OMIC N/A
- Industry
- GRCE
- OMIC Medical/Dental Instruments
- Sector
- GRCE
- OMIC Health Care
- Exchange
- GRCE NYSE
- OMIC Nasdaq
- Market Cap
- GRCE 30.9M
- OMIC 34.9M
- IPO Year
- GRCE N/A
- OMIC 2021
- Fundamental
- Price
- GRCE $3.31
- OMIC $22.73
- Analyst Decision
- GRCE
- OMIC Hold
- Analyst Count
- GRCE 0
- OMIC 2
- Target Price
- GRCE N/A
- OMIC $10.75
- AVG Volume (30 Days)
- GRCE 44.3K
- OMIC 35.1K
- Earning Date
- GRCE 11-13-2024
- OMIC 11-12-2024
- Dividend Yield
- GRCE N/A
- OMIC N/A
- EPS Growth
- GRCE N/A
- OMIC N/A
- EPS
- GRCE N/A
- OMIC N/A
- Revenue
- GRCE N/A
- OMIC $2,667,000.00
- Revenue This Year
- GRCE N/A
- OMIC $10.41
- Revenue Next Year
- GRCE N/A
- OMIC $222.15
- P/E Ratio
- GRCE N/A
- OMIC N/A
- Revenue Growth
- GRCE N/A
- OMIC 2.77
- 52 Week Low
- GRCE $1.98
- OMIC $5.34
- 52 Week High
- GRCE $3.60
- OMIC $23.41
- Technical
- Relative Strength Index (RSI)
- GRCE N/A
- OMIC 72.38
- Support Level
- GRCE N/A
- OMIC $21.56
- Resistance Level
- GRCE N/A
- OMIC $23.00
- Average True Range (ATR)
- GRCE 0.00
- OMIC 1.19
- MACD
- GRCE 0.00
- OMIC 0.64
- Stochastic Oscillator
- GRCE 0.00
- OMIC 92.01
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
About OMIC Singular Genomics Systems Inc.
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.